apollo

Online Doctor Consultation & Medicines

Hello,

Select your location

Special offers

  1. Home
  2. Apnicaf Oral Solution 3 ml

Apnicaf Oral Solution 3 ml

Manufacturer/Marketer

Abbott India Ltd

Consume Type

ORAL

In Stock

Prescription Required
Product Details

About Apnicaf Oral Solution 3 ml

Apnicaf Oral Solution 3 ml belongs to a group of medicines known as methylxanthines. It is used to treat primary apnoea of premature newborns (interrupted breathing in premature babies). Apnea is a condition where breathing interrupts and causes abnormal heart rate and oxygen saturation alterations. It is a common occurrence, particularly in premature infants.

Apnicaf Oral Solution 3 ml contains 'Caffeine Citrate', which belongs to the central nervous system (CNS) stimulants class. It works in three different ways. Firstly, it is the adenosine receptor antagonist; secondly, it is a phosphodiesterase inhibitor. And thirdly, it is an active intracellular calcium mobiliser. Collectively Caffeine stimulates the respiratory centre, sensitising it to hypercapnia. Thereby Apnicaf Oral Solution 3 ml effectively regulates the mean respiratory rate and tidal volume, improves pulmonary blood flow, decreases carbon dioxide sensitivity and enhances diaphragmatic function and breathing pattern.

Apnicaf Oral Solution 3 ml should be used as prescribed by your doctor. Your doctor will determine the suitable dosage based on your infant's medical conditions. In some cases, Apnicaf Oral Solution 3 ml can cause side effects like tachycardia (fast heartbeat), arrhythmia (irregular heartbeat) and hyperglycaemia (increased sugar in blood or serum). These side effects are not prevalent and vary from person to person. Consult your doctor if these symptoms continue or worsen. They may be able to recommend strategies to avoid or minimise certain side effects.

Inform your doctor about the complete medical history of your infant. If you are nursing your infant is being treated with this medication, avoid drinking coffee or using any other caffeine-containing products since Caffeine passes into breast milk. This medication should be used with caution in infants with impaired hepatic or renal function. Before fixing the dose, your doctor may assess baseline serum caffeine levels in children born to caffeine-consuming mothers.

Uses of Apnicaf Oral Solution 3 ml

Primary apnea of premature newborns/neonates.

Medicinal Benefits

Apnicaf Oral Solution 3 ml contains 'Caffeine Citrate', which belongs to the central nervous system (CNS) stimulants class. It works in three different ways. Firstly, it is the adenosine receptor antagonist; secondly, it is a phosphodiesterase inhibitor. And thirdly, it is an active intracellular calcium mobiliser. Collectively Caffeine stimulates the respiratory centre, sensitising it to hypercapnia. Thereby Apnicaf Oral Solution 3 ml effectively regulates the mean respiratory rate and tidal volume, improves pulmonary blood flow, decreases carbon dioxide sensitivity and enhances diaphragmatic function and breathing pattern.

Directions for Use

Apnicaf Oral Solution 3 ml should be used under medical supervision.

Storage

Store in a cool and dry place away from sunlight

Side Effects of Apnicaf Oral Solution 3 ml

  • Tachycardia (fast heartbeat)
  • Hyperglycaemia (increased sugar in blood or serum)
  • Arrhythmia (irregular heartbeat)

In-Depth Precautions and Warning

Drug Warnings

Inform your doctor about your infant's medical history. If you are breastfeeding and your infant is being treated with this medication, avoid drinking coffee or using any other caffeine-containing products since caffeine passes into breast milk. Apnicaf Oral Solution 3 ml should only be used in a neonatal intensive care unit where adequate patient surveillance and monitoring facilities are available. Treatment should begin under the supervision of a neonatologist with experience in neonatal intensive care. This medication should be used with caution in infants with impaired liver or kidney function.

Drug Interactions

Drug-Drug Interaction: No interactions were found or established.

Drug-Food Interaction: No interactions were found or established.

Drug-Disease Interaction: No interactions were found or established.

Drug-Drug Interactions Checker List:

Safety Advice

  • Safety Warning

    Alcohol

    caution

    Apnicaf Oral Solution 3 ml is intended to use in premature newborns/neonates.

  • Safety Warning

    Pregnancy

    caution

    Apnicaf Oral Solution 3 ml is recommended to be used only in infants.

  • Safety Warning

    Breast Feeding

    caution

    Apnicaf Oral Solution 3 ml is intended for use in newborns/neonates only. If your infant is being treated with this medication, avoid drinking coffee or using any other caffeine-containing products since caffeine passes into breast milk.

  • Safety Warning

    Driving

    caution

    Apnicaf Oral Solution 3 ml is intended to use in premature newborns/neonates.

  • Safety Warning

    Liver

    caution

    Apnicaf Oral Solution 3 ml should be used with caution in infants with impaired hepatic or liver function.

  • Safety Warning

    Kidney

    caution

    Apnicaf Oral Solution 3 ml should be used with caution in infants with impaired renal or kidney function.

  • Safety Warning

    Children

    caution

    Apnicaf Oral Solution 3 ml is intended to use in premature newborns/neonates.

Habit Forming

No

Other Information (APN0015)

This item is Not Returnable.

Expires on or after - Sep-23

Patients Concern

Disease/Condition Glossary

Apnea: Apnea is an interruption of breathing that causes abnormal heart rate and oxygen saturation alterations. It is a common occurrence, particularly in premature infants. Apnea can arise as a result of central nervous system immaturity (apnea of prematurity) or as a result of other factors such as metabolic abnormalities, etc. 

FAQs

Apnicaf Oral Solution 3 ml contains 'Caffeine Citrate', which belongs to the central nervous system (CNS) stimulants class. It works in three different ways. Firstly, it is the adenosine receptor antagonist; secondly, it is a phosphodiesterase inhibitor. And thirdly, it is an active intracellular calcium mobiliser. Collectively Caffeine stimulates the respiratory centre, sensitising it to hypercapnia. Thereby Apnicaf Oral Solution 3 ml effectively regulates the mean respiratory rate and tidal volume, improves pulmonary blood flow, decreases carbon dioxide sensitivity and enhances diaphragmatic function and breathing pattern.

No, it is intended to treat primary apnoea of premature newborns/neonates.

The dosage is determined by your baby's weight, medical problems, and responsiveness to therapy. Before determining the dose, it is also necessary to establish the baseline serum caffeine levels in children born to caffeine-consuming mothers.

PRODUCT SUBSTITUTES

Apnicaf Oral Solution 3 ml

Country Of Origin

India

Manufacturer/Marketer address

16th Floor, Godrej BKC, Plot – C, “G” Block, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051, India

Disclaimer

While we strive to provide complete, accurate, and expert-reviewed content on our 'Platform', we make no warranties or representations and disclaim all responsibility and liability for the completeness, accuracy, or reliability of the aforementioned content. The content on our platform is for informative purposes only, and may not cover all clinical/non-clinical aspects. Reliance on any information and subsequent action or inaction is solely at the user's risk, and we do not assume any responsibility for the same. The content on the Platform should not be considered or used as a substitute for professional and qualified medical advice. Please consult your doctor for any query pertaining to medicines, tests and/or diseases, as we support, and do not replace the doctor-patient relationship.

(Inclusive of all taxes)

Provide Delivery Location

Vial

1

3 ml Suspension in 1 Vial